Ultragenyx Pharmaceutical (RARE) Operating Income Growth (1y) (2014 - 2026)
Ultragenyx Pharmaceutical (RARE) Operating Income Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | 2,150.96% |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | 145.20% |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | 1,386.07% |
| 10 | Ultragenyx Pharmaceutical | 2.73 Bn | 2.32 Bn | 106.00 Mn | -18.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.18% |
| Dec 31, 2025 | 7.38% |
| Sep 30, 2025 | -29.47% |
| Jun 30, 2025 | 7.28% |
| Mar 31, 2025 | 13.52% |
| Dec 31, 2024 | -0.38% |
| Sep 30, 2024 | 9.04% |
| Jun 30, 2024 | 21.35% |
| Mar 31, 2024 | -7.30% |
| Dec 31, 2023 | 16.33% |
| Sep 30, 2023 | 35.53% |
| Jun 30, 2023 | -4.49% |
| Mar 31, 2023 | -12.79% |
| Dec 31, 2022 | -41.99% |
| Sep 30, 2022 | -150.55% |
| Jun 30, 2022 | -71.06% |
| Mar 31, 2022 | -28.21% |
| Dec 31, 2021 | -6.75% |
| Sep 30, 2021 | -78.53% |
| Jun 30, 2021 | -31.28% |